Aravive (ARAV) Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ARAV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARAV, but not buy additional shares or sell existing shares.
View ARAV analyst ratings or view top-rated stocks.

6 analysts have issued 12-month target prices for Aravive's shares. Their ARAV share price forecasts range from $2.00 to $18.00. On average, they expect the company's share price to reach $10.17 in the next twelve months. This suggests a possible upside of 7,649.0% from the stock's current price.
View analysts price targets for ARAV or view top-rated stocks among Wall Street analysts.

Aravive's stock was trading at $1.32 at the start of the year. Since then, ARAV shares have decreased by 90.1% and is now trading at $0.1312.
View the best growth stocks for 2023 here.

Aravive saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 7,300,000 shares, an increase of 62.9% from the August 31st total of 4,480,000 shares. Based on an average trading volume of 6,950,000 shares, the days-to-cover ratio is currently 1.1 days.
View Aravive's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our ARAV earnings forecast.

Aravive, Inc. (NASDAQ:ARAV) announced its earnings results on Monday, August, 21st. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.18. The company had revenue of $1.27 million for the quarter, compared to analyst estimates of $1 million. Aravive had a negative trailing twelve-month return on equity of 1,865.78% and a negative net margin of 834.54%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aravive investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Applied Genetic Technologies (AGTC), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Arbutus Biopharma (ABUS) and BioCryst Pharmaceuticals (BCRX).

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

Aravive's stock is owned by many different retail and institutional investors. Top institutional shareholders include Affinity Asset Advisors LLC (0.00%), BlackRock Inc. (0.54%), Geode Capital Management LLC (0.51%), Renaissance Technologies LLC (0.36%) and Assenagon Asset Management S.A. (0.03%). Insiders that own company stock include Amato Giaccia, Gail Frances Mcintyre and Vinay Shah.
View institutional ownership trends.

Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARAV stock can currently be purchased for approximately $0.13.

Aravive (NASDAQ:ARAV) has a market capitalization of $9.65 million and generates $9.14 million in revenue each year. The company earns $-76,320,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis.

Aravive's mailing address is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. The official website for the company is www.aravive.com. The company can be reached via phone at (936) 355-1910 or via email at christina@sternir.com.